The Cannabis derived product Epidiolex, produced by GW Pharmaceuticals, was just approved by the United States Food and Drug Administration for the treatment of Lennox-Gastaut syndrome and Dravet syndrome—which are both rare forms of epilepsy. For the first time since its prohibition, a product truly derived from Cannabis has been recognized to have medical application in the United States. In the published study found here and in the final report delivered to the FDA found h

Our humble president recently made a comment regarding Cannabis that’s suddenly been butchered and overanalyzed to the point of stirring some major attention. What was said was that he would likely support a congressional effort to end the blanket federal ban on Cannabis. This would simply give states the right to decide their own Cannabis policy—effectively doing nothing to re-shape the Controlled Substances Act or Cannabis’ implications at the federal level. His comment did